From Wikipedia, the free encyclopedia
  (Redirected from SEP-225,289)
Jump to: navigation, search
Systematic (IUPAC) name
CAS Number 675126-05-3 YesY
PubChem CID 9947999
ChemSpider 8123611 N
Chemical data
Formula C16H15Cl2N
Molar mass 292.20 g·mol−1
 NYesY (what is this?)  (verify)

Dasotraline (INN)[1] (former developmental code name SEP-225,289) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that is under development by Sunovion for clinical use.[2][3][4][5] The drug is no longer being developed for major depressive disorder (MDD), but is still under investigation for the treatment of attention-deficit hyperactivity disorder (ADHD) and eating disorders.[6][7] Structurally, dasotraline is a stereoisomer of desmethylsertraline, which is an active metabolite of the marketed selective serotonin reuptake inhibitor (SSRI) antidepressant sertraline (Zoloft) and an SNDRI similarly.

Side Effects[edit]

In phase I trials for ADHD, test subjects reported the following side effects:[8][9]

See also[edit]


  1. ^ "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). WHO Drug Information. WHO. 27 (4). 2013. Retrieved 4 November 2014. 
  2. ^ Chen, Zhengming; Skolnick, Phil (2007). "Triple uptake inhibitors: therapeutic potential in depression and beyond". Expert Opinion on Investigational Drugs. 16 (9): 1365–77. doi:10.1517/13543784.16.9.1365. PMID 17714023. 
  3. ^ DeLorenzo, C.; Lichenstein, S.; Schaefer, K.; Dunn, J.; Marshall, R.; Organisak, L.; Kharidia, J.; Robertson, B.; Mann, J. J.; Parsey, R. V. (2011). "SEP-225289 Serotonin and Dopamine Transporter Occupancy: A PET Study". Journal of Nuclear Medicine. 52 (7): 1150–5. doi:10.2967/jnumed.110.084525. PMC 3856248free to read. PMID 21680689. 
  4. ^ Ziegler, L.; Küffer, G.; Euler, E.; Wilhelm, K. (1990). "Arthrographische Darstellung von Ganglien im Handbereich" [Arthrographic imaging of ganglions of the hand]. RöFo (in German). 153 (2): 143–6. doi:10.1055/s-2008-1033352. PMID 2168068. 
  5. ^ Guiard, B.; Chenu, F.; El Mansari, M.; Blier, P. (2009). "P.1.c.059 Electrophysiological properties of the triple reuptake inhibitor SEP 225289 on monoaminergic neurons". European Neuropsychopharmacology. 19: S285. doi:10.1016/S0924-977X(09)70419-5. 
  6. ^ Clinical trial number NCT02276209 for "Dasotraline Adult ADHD Study" at ClinicalTrials.gov
  7. ^ http://adisinsight.springer.com/drugs/800023450[full citation needed]
  8. ^ Koblan, Kenneth S; Hopkins, Seth C; Sarma, Kaushik; Jin, Fengbin; Goldman, Robert; Kollins, Scott H; Loebel, Antony (2015). "Dasotraline for the Treatment of Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Trial in Adults". Neuropsychopharmacology. 40 (12): 2745–52. doi:10.1038/npp.2015.124. PMC 4864650free to read. PMID 25948101. 
  9. ^ http://www.additudemag.com/adhdblogs/19/11101.html[full citation needed]

Further reading[edit]

Liming Shao Patent
  • US application 2007203111, Shao L, Wang F, Malcolm SC, Hewitt MC, Bush LR, Ma J, Varney MA, Campbell U, Engel SR, Hardy LW, Koch P, Campbell JE, "Cycloalkylamines as monoamine reuptake inhibitors", published 2007-08-30, assigned to Sepracor Inc. 
Asymmetry Patent
  • US patent 7129378, Han X, Krishnamurthy D, Senanayake CH, Lu Z-H, "Method of preparing amine stereoisomers", published 2005-07-28, assigned to Apsinterm LLC